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Abstract Weightlosshasbeenrecognized as a feature of advancedemphysema and a factorof poorprognosis, but its
mechanisms remain obscure. Studies have demonstrated high serum concentrations of TNF-a (cachexin) in chronic ob-
structive pulmonarydisease (COPD) patientswith emphysema.Pinkpuffers (PP) COPD patientshaveworse tissueoxy-
genation when compared with blue bloaters (BB) COPD patients.Consequently, PP patients would become cachectic,
whereas BB patientswith better tissue oxygenationwouldnot.The aimofthis studyis to testthe hypothesis thatmalnu-
trition in emphysema is a cytokine-mediatedmarker of chronic progressive tissue hypoxia.Thirtymale COPD patients,
withoutclinical or laboratoryevidence of infection and severe airwayobstruction (FEV1o1.5 l) were allocated:16 aspink
puffers (PP) and 14 as blue bloaters (BB). Lung function measurements included FEV1, FVC,RV,TLC, DLCO and arterial
blood gases on room air.TNF-a serum levels were measured by immunoenzymic method (ELISA).Tissue oxygenation
was assessed fromoxygendelivery (DO2),PvO2 andoxygenextractionratio (O2ER) obtainedafterrightheart catheter-
ization with Swan Ganz catheter. PP patients demonstrated lower DLCO and higherTLC, FRC and PaO2 from BB.We
found that oxygen delivery was better in our BB than in PP patients (Cl 2.9+0.2 vs 2.5+0.4 l/min/m2--Po0.01, DO2
16.1+2.1 vs 13.1+0.2ml/min/kgPo0.001) and the same was found for tissue oxygenation (PvO2 34.6+2.9 vs
31.2+3.8mmHg-Po0.01,O2ER 0.27+0.02 vs 0.34+0.06%-Po0.001).TheTNF-a values were higher in PP (31.3+26 pg/
mlvs15.2+9.9 pg/ml-Po0.05) and their percent fat-freemass (%FFM) was 49.6+11.5 vs 42+8%-Po0.001.We found that
COPD patientswithlower DO2 hadincreased TNF-a levels; butthe correlationsbetweenTNF-a serumlevels and PvO2
or O2ERwere not statistically significant.TNF-a levels were elevated in PP patients with tissue hypoxia and may be a
factor contributing to theweight loss of these patients.r2002 Publishedby Elsevier Science Ltd
doi:10.1053/rmed.2002.1322, available online athttp://www.idealibrary.comon
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The patterns of chronic obstructive pulmonary disease
(COPD) can be distinguished clinically: the pink and puf-
fering (PP) patient is characteristically thin, breathless,
with marked hyperin£ation of the chest without central
cyanosis. Arterial bloodgas analysis showsmoderate hy-
poxiawith normal or low PaCO2.Earlier ideas that these
PP patients were predominantly associatedwith emphy-
sema cannot be satisfactorily sustained by clinopatholo-
gical correlations. The ‘‘blue and bloater’’ (BB) patient
may not be particularly breathless, at least at rest, but
has severe central cyanosis with signs of cor pulmonal.
The arterial PaO2 is characteristically low and theReceived16 May 2001, accepted in revised form 5 February 2002.
Correspondence should be addressed to:D.Patakas. Pulmonary Clinic,
G. Papanikolaou Hospital, Exohi,Thessaloniki 57010,Greece.
Fax: +31350253.PaCO2 is high. Earlier concept that BB patients had pre-
dominantly bronchitis with little emphysema has now
also proved to be an error. In contrast to PP, in BB pa-
tients tissue oxygen perfusion and oxygenation is com-
promised because of increased cardiac output and
preserved oxygen content (1).
Weight loss commonly occurs in patients with emphy-
sema and it was associated with considerably increased
morbidity and mortality (1,3).There are several hypoth-
esis addressing mechanisms of weight loss in COPD pa-
tients: hypermetabolism (4,5), arising from the
increased work of breathing in emphysematous patients
resulting in increased energy expenditure, negative en-
ergy balance and weight loss is one of them. However,
patients with COPD, who loseweight are not always hy-
permetabolic, whilepatientswith similar increases in the
work of breathing, due to other respiratory diseases do
not exhibit weight loss (6).
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the role of cytokines in the pathogenesis of weight loss.
Studies of tumor necrosis factor-a (TNF-a) in patients
with COPD showed that not only serum concentrations
of cytokines are high in COPD with weight loss (7), but
also thatmonocytes frommalnourished COPD patients
release a larger amount of cytokines spontaneously and
in response to stimulation (8). Also priming of human
monocytes by hypoxia in vitro enhances cytokine release
(9).The sequence of events leading to cachexia may oc-
cur in tissue hypoxic pink pu¡er patients, whereas in
bronchitis patients with relative compromised tissue
oxygenation (10) would not.
The aimof this study is to examine thehypothesis that
weight loss in emphysematous patients might be asso-
ciatedwith cytokine activity driven by tissue hypoxia.
MATERIALANDMETHODS
Subjects
This study population consisted of 30 men with stable
COPD. All patients admitted to our clinic with the diag-
nosis of severe chronic airway obstruction (Stage II or III
according to the criteria of the AmericanThoracic So-
ciety (11, 23).They were studied under stable clinical and
functional condition and gave informed consent. The
study was approved by the Ethical Committee of G. Pa-
panikolaou Hospital.
Exclusion criteriawere: evidence of pitting edema; oc-
currence of COPD symptoms exacerbation during the
previous 4 weeks; conditions known to be associated
with elevated TNF-a blood levels: collagen diseases, con-
gestive cardiac failure, liver or renal diseases, cancer, and
infection. To rule out respiratory infection, the patients
had to ful¢ll the following criteria: temperatureo371C,
blood WBC o9.000/mm3, erythrocyte sedimentation
rate o20mm/h, absence of parenchymal in¢ltrates in
chest X-rays and absence or usual amount of sputum
production.
Our patients were allocated into two groups: pink
pu¡ers (PP) and blue bloaters (BB).The pink pu¡ers pa-
tients are thin, breathless with marked hyperin£ation of
chestwithoutcyanosis andwith normal PaCO2.Theblue
bloaters were less breathless with central cyanosis, ele-
vated PaCO2 andwith clinical or ECG signs of corpulmo-
nale.
All of the patients were treated with inhaled
bronchodilators and corticosteroids. None of themwas
on oral corticosteroids. Seven of the BB patients were
on diuretics.
Methods
Lung volumes, expiratory £ow rates and di¡using capa-
city (single breath CO) were measured with a spirom-eter ( Jaeger Transferscreen II) according to current
guidelines. Measurements of static lung volumes were
madewith theheliumdilutionmethod.Thepredicted va-
lues were those of Cotes (12). Arterial blood gas (PaO2
and PaCO2) and pH weremeasured at rest with a blood
gas analyzer (ABC 300; Radiometer).
Body mass index (BMI) was assessed from patient,
weight and height.Fat-freemass (FFM) of the body (lean
body mass) was calculated from body weight and the
thickness of the skin plus subcutaneous tissues, which
provide ameasure of body fat.The thickness ismeasured
at four sites on the left side of the body using a skin cali-
per ( John Bull). The fat-free mass (FFM) is estimated
from the equation FFM%=bodymass (100%fat)/100.
Blood was obtained in fasting state in the morning,
into blood collection tubes containing 50U of heparin.
Plasma was separated from blood cells by centrifugation
at 1000g for 5min, within 1h after collection. Plasma
sampleswere storedat 20oCuntil analysisTNF-ameasur-
ing using a speci¢c sandwich ELISA (13).
Right heart catheterization was performed using a
No. 7 Swan-Ganz catheter through an antecubital vein.
Oxygen content (CO2) was measured in pulmonary and
arterial blood samples (CO2=1.34HbSO2%+PO2 0.03).
Expired air was collected andmeasured in aDouglas bag
and analyzed for CO2 andO2 concentrations with a CO2
Datex-Normocap 200 and Jaeger O2 analyzers properly
calibrated.Oxygen consumption per min (VO2) was cal-
culated from the equation: VO2=VE STPD (0.2648-
FEN2-FEO2) when FEN2 = concentration of N2 in expira-
tory air, FEN2=1(FEO2+FECO2) (11).Cardiac output (Q)
measured from the Fick equation Q= VO2/CaO2CvO2
and expressed as cardiac index (Cl), Cl=Q/BSE.Oxygen
delivery (DO2) was calculated from the equation
DO2=CaO2Q, where CaO2=oxygen content of arter-
ial blood.Oxygen extraction ratio (O2ER)was calculated
from the equation: OER=CaO2CvO2/CaO2 (14).
Data between the two groups were analyzed by an
unpaired t -test. Tissue hypoxia indices were related to
other variables by linear regression. The Po0.05 was
considered statistically signi¢cant. Values were ex-
pressed asmean+SD.
RESULTS
Sixteen of our COPD patient ful¢lled the clinical and la-
boratory criteria of pink pu¡ers and14 of the blue bloa-
ters. A comparison of the two groups using
demographic, spirometric and blood gases data is pre-
sented inTable1.The heights were equivalent in the two
patient groups, but the PP patients were underweight.
There was no di¡erences in the degree of air£ow ob-
struction between the two groups but PP patients
had lower DLCO and higher lung hyperin£ation. The BB






Age (years) 63.2+8 64+9 NSa
Height (cm) 167+5.3 168+4.4 NS
Weight (kg) 65.3+9.1 77.1+14 po0.01
BMI 23.8+3.3 27.1+4.8 Po0.01
FFM (%) 58.4+8 42+9 Po0.05
FEV1 (% pred) 39+12 41+10 NS
FVC (% pred) 67+21 62+21 NS
FRC (% pred) 117+23 75+19 Po0.001
TLC (% pred) 108+21 88+14 Po0.001
DLCO (ml/min/mmHg) 9.8+3.6 20.5+4 Po0.001
PaO2(mmHg) 64.7+9.6 54.8+7.1 Po0.01
PaCO2 (mmHg) 39.3+1.8 48.6+4.2 Po0.001
aNS: di¡erence not signi¢cant.
Note: Data are presented as mean+SD.BMI, body mass index; FFM, fat-free mass; FEV1, forced expiratory volume in 1s; FVC,
forcedvital capacity;FRC, functionalresidual capacity;TLC, totallungcapacity;DLCO, di¡usingcapacity.
596 RESPIRATORYMEDICINEpatients were more hypercapnic and hypoxic than the
patients with emphysema.
The data describingO2 uptake, the tissue oxygenation
indices and the TNF-a serum levels in the two patient
groups are presented in Table 2. The resting VO2 ex-
pressed inml/kg/min to standardize these values relative
to body mass was elevated in PP patients when com-
pared to the group of BB patients (o0.01). The resting
Cl and DO2(ml/min/kg) were signi¢cantly elevated in BB
patients.The PvO2 was signi¢cantly lower in PP patients
(Po0.01) and the O2ERwas found to be lower in BB pa-
tients (Po0.001). Also, TNF-a serum concentrations
were signi¢cantly higher in PP patients (Po0.05).
The resting VO2 expressed in ml/min/kg was signi¢-
cantly higher in patients having elevated TNF-a serum le-
vels (t=0.366, Po0.05). Analyzing the oxygen delivery
and tissue oxygenation indices, we found that patients










Data are presented asmean+SD.
VO2, oxygenuptake;CI, cardiac index;DO2, oxygen delivery;Oum levels (r=0.362 Po0.05); in contrast no statistically
signi¢cant relationship was demonstrated betweenTNF-
a serum levels and PvO2 or O2ER.
DISCUSSION
The relative tissue hypoxia of PP in contrast with the
well-preserved tissue oxygenation and O2 transport of
BB was noticed several years ago (10,15). Among our pa-
tients with COPD thosewho fought to preserve relative
normal arterial blood gases (PP) had low resting cardiac
output and PvO2 and widened extraction ratio of oxy-
gen. In contrast, blue bloaters hypoventilated, retained
CO2 and were hypoxic but resting cardiac output and
DO2was increased andoxygen transport and tissueoxy-












TUMORNECROSIS FACTORINCOPD 597TNF-a serum levels were signi¢cantly higher in our PP
patients. Elevated TNF-a blood levels have been docu-
mented in various human diseases associated with
weight loss (16). Experimentally,TNF-a stimulates energy
expenditure by acting on protein and lipid metabolism,
reduces energy intake via its anorectic e¡ect and causes
cachexia (17).TheTNF-a serum levels were higher in our
patients with emphysema and these patients had signi¢-
cantly lower body weight, BMI and higher percent FFM
when compared to our patients with bronchitis.
The increase TNF-a serum levels in our PP patients
could result from increased production or decreased
clearance. The kidney is responsible for extraction and
catabolism of TNF-a (18). Because renal function in our
two groups was within normal range, a di¡erence in
TNF-a clearance was unlikely to be responsible for in-
creased serum levels of TNF-a of patients with emphyse-
ma. Increased production could not be explained by
respiratory or no respiratory infections because we
tookcare not to includepatientswith clinical and labora-
tory signs of infection. If aminor degree of infectionswas
nevertheless present, it is more possible to be underde-
tected in bronchitic and not in emphysematous patients;
but TNF-a serum levels were lower in patients with
bronchitis.
Increased production of TNF-a serum levels can also
be related to tissue hypoxia. Studies of TNF-a in COPD
patients demonstrated that not only serum concentra-
tions are high in malnourished COPD patients (6) but
also monocytes from those with weight loss produce a
large amount of cytokines spontaneously and in re-
sponse to stimulation (7). Priming of human monocytes
by hypoxia in vitro enhances cytokine release (8), and this
sequence of eventsmayoccur in tissuehypoxic PP COPD
patients. In contrast, bronchitic patients who preserved
adequate tissue oxygenation had lowerTNF-a serum le-
vels.
TNF-a serum levels were on average more than 2
times higher in patients with emphysema when com-
pared to the values obtained in patients with bronchitis
(Po0.05).TheTNF-a serum levels in several patientswith
bronchitis (6) were above the normal values (7.9+2.7).
Analyzing our COPD patients together, we found that
patients with lower oxygen delivery (DO2) also had in-
creased TNF-a serum levels, but we were unable to de-
monstrate any statistically signi¢cant correlation
between TNF-a serum levels and O2ER or PvO2. This
probably was related to the fact that TNF-a was irregu-
larly produced under the in£uence of di¡erent stimuli
(infection, hypoxia).The observation thatweight loss fol-
lows a stepwise decrease in several COPD patients (19)
¢ts thehypothesis of intermittentTNF-a production. It is
also possible that TNF-a serum levels do not accurately
re£ect tissue production, because the serum half-life of
TNF-a is approximately only 6^7min and for these rea-
sons periods of TNF-a production have beenmissed.There are not any unifying hypotheses addressing the
mechanism of weight loss in several patients with COPD
(20).Many authors believe thatweight loss related to hy-
permetabolism due to elevatedworkof breathing (4,22),
ventilatory muscle insu⁄ciency resulting in greater en-
ergy demand per amount of work performed (4), and
medications, since theophilline, b-agonist compounds
can stimulate metabolism (22). In our thin PP patients
the resting VO2 (ml/min/kg) was signi¢cantly higher than
that of BB, indicating a relative hypermetabolic state. A
secondhypothesis states thatmalnutrition in pink pu¡er
patients is a cytokine-mediated marker of chronic pro-
gressive tissue hypoxia.Weight loss, being the result of
gas exchange abnormality, would be a re£ection of wor-
sening tissue oxygenation and not worsening of air£ow
obstruction.The onset of weight loss would thus signify
advancing tissue hypoxia, even in patients with relative
normal arterial PO2. The hypoxia-induced cytokine ac-
tivity is further enhanced from in£ammatory activity as-
sociatedwith infection and other stresses.
The tissue hypoxia noted in the pink pu¡er patients is
associated with activation of TNF-a system, which may
be a factor contributing to the weight loss of these pa-
tients.
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